Show simple item record

dc.contributor.authorAguado, Tania
dc.contributor.authorHuerga Gómez, Alba
dc.contributor.authorSánchez de la Torre, Aníbal
dc.contributor.authorResel, Eva
dc.contributor.authorChara Ventura, Juan Carlos
dc.contributor.authorMatute Almau, Carlos José
dc.contributor.authorMato Santos, Susana ORCID
dc.contributor.authorGalve-Roperh, Ismael
dc.contributor.authorGuzmán, Manuel
dc.contributor.authorPalazuelos, Javier
dc.date.accessioned2022-01-07T11:01:25Z
dc.date.available2022-01-07T11:01:25Z
dc.date.issued2021-10
dc.identifier.citationBritish Journal of Pharmacology 178(20) : 4176-4192 (2021)es_ES
dc.identifier.issn0007-1188
dc.identifier.issn1476-5381
dc.identifier.urihttp://hdl.handle.net/10810/54833
dc.description.abstractBackground and purpose Research on demyelinating disorders aims to find novel molecules that are able to induce oligodendrocyte precursor cell differentiation to promote central nervous system remyelination and functional recovery. Delta(9)-Tetrahydrocannabinol (THC), the most prominent active constituent of the hemp plant Cannabis sativa, confers neuroprotection in animal models of demyelination. However, the possible effect of THC on myelin repair has never been studied. Experimental approach By using oligodendroglia-specific reporter mouse lines in combination with two models of toxin-induced demyelination, we analysed the effect of THC on the processes of oligodendrocyte regeneration and functional remyelination. Key results We show that THC administration enhanced oligodendrocyte regeneration, white matter remyelination and motor function recovery. THC also promoted axonal remyelination in organotypic cerebellar cultures. THC remyelinating action relied on the induction of oligodendrocyte precursor differentiation upon cell cycle exit and via CB1 cannabinoid receptor activation. Conclusions and implications Overall, our study identifies THC administration as a promising pharmacological strategy aimed to promote functional CNS remyelination in demyelinating disorders.es_ES
dc.description.sponsorshipCentro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas, Grant/Award Numbers: CB06/0005/0076, CB06/05/0005; Comunidad de Madrid, Grant/Award Numbers: 2016-T1/BMD-1060, 20205A/BMD-19728; Basque Government (Eusko Jaurlaritza), Grant/Award Numbers: IT1203-19, PIBA19-0059; Fondation pour l'Aide a la Recherche sur la Sclerose en Plaques, ARSEP Foundation; Fundacion Tatiana Perez de Guzman el Bueno; FEDER and Instituto de Salud Carlos III, Grant/Award Numbers: PI18-00941, PI18/00513; Ministerio de Economia y Competitividad, Grant/Award Numbers: PID2020-112640RB-I00, RTI2018095311-B-I00, SAF2016-75292-R, SAF2017-83516es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/PID2020-112640RB-I00es_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/RTI2018095311-B-I00es_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SAF2016-75292-Res_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SAF2017-83516es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectcannabinoidses_ES
dc.subjectCB1 cannabinoides_ES
dc.subjectreceptores_ES
dc.subjectdemyelinating disorderses_ES
dc.subjectmTORC(1)es_ES
dc.subjectoligodendrocyte precursor cellses_ES
dc.subjectremyelinationes_ES
dc.subjectTHCes_ES
dc.subjectexperimental autoimmune encephalomyelitises_ES
dc.subjectcuprizone-induced demyelinationes_ES
dc.subjectprogressive multiple-sclerosises_ES
dc.subjectoligodendrocyte lineage cellses_ES
dc.subjectcannabinoid receptorses_ES
dc.subjectCNSes_ES
dc.subjectmodeles_ES
dc.subjectmyelines_ES
dc.subjectcannabidioles_ES
dc.subjectsuppressiones_ES
dc.titleDelta(9)-Tetrahydrocannabinol promotes functional remyelination in the mouse braines_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in anymedium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.© 2021 The Authors.British Journal of Pharmacologypublished by John Wiley & Sons Ltd on behalf of British Pharmacological Society.es_ES
dc.rights.holderAtribución-NoComercial-SinDerivadas 3.0 España*
dc.relation.publisherversionhttps://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.15608es_ES
dc.identifier.doi10.1111/bph.15608
dc.departamentoesNeurocienciases_ES
dc.departamentoeuNeurozientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in anymedium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.© 2021 The Authors.British Journal of Pharmacologypublished by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Except where otherwise noted, this item's license is described as This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in anymedium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.© 2021 The Authors.British Journal of Pharmacologypublished by John Wiley & Sons Ltd on behalf of British Pharmacological Society.